Women's Health

Lilly's CDK 4/6 inhibitor a cancer contender

Lilly's CDK 4/6 inhibitor a cancer contender

By

Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.

Pfizer palbociclib news divides investors

Pfizer palbociclib news divides investors

By

Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.

FDA wants parents to back off fetus selfies

The regulator says at-home ultrasounds and heart monitoring systems are a bad idea.

Study shows HPV vax impact

Queensland, Australia, researchers find the risk of high-grade cervical abnormalities fell 46% among women who had received all three doses of the HPV vaccine.

FDA ends Teva Plan B OTC dominance

The regulator is allowing generic makers room on the OTC contraceptive shelf.

Advil hearts menstrual cramps

Advil hearts menstrual cramps

By

Pfizer's consumer website for Advil in South Korea offers a strange appeal to women who experience menstrual pain.

Merck sends HPV vax to FDA

Merck sends HPV vax to FDA

By

The drugmaker's new vaccine has more brawn, but vaccination rates among boys and girls remain low.

Panel urges increased HPV vaccination rates

Hitting a vaccination rate of 80% of girls would mean 53,000 fewer cases of cervical cancer.

Merck may be near NuvaRing settlement

The drugmaker may be able to settle around 3,800 cases for $100 million.

Birth control football remains in play

The White House has until Friday to issue a response to a Supreme Court injunction that temporarily eased birth-control coverage requirements.

Viagra population could double

A Penn State researcher thinks it can help women with menstrual cramps.

Analyst: Don't underestimate AbbVie

Analyst: Don't underestimate AbbVie

By

Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.

Pediatricians want greater condom access

The AAP says greater access and education are critical in curbing STIs.

Roche posts sales increase

Roche posts sales increase

By

Sales of its breast cancer treatments boosted totals for the first nine months of 2013, along with diagnostics, which saw a 3% increase over last year.

Quest joins breast cancer gene-testing market

The diagnostics firm is undercutting Myriad's cost by almost $1,000.

Bayer: 5 new Phase III drugs expected in 2015

The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.

Merck reorg reimagines sales force

Merck reorg reimagines sales force

By

The company will "fill the bag" of its sales reps, as part of a reorganization that also includes 8,500 job cuts and a more refined R&D focus.

FDA okays Perjeta for first-line breast cancer treatment

FDA okays Perjeta for first-line breast cancer treatment

By

The second-line drug sped from Priority Review status for the first-line indication to approval in just over two months.

Breast cancer risk awareness shown lagging

By

Researchers surveying 21 Long Island mammography centers found that women do not know their risk.

Novo taps five experts for their brash take on menopause

Novo taps five experts for their brash take on menopause

By

The drug maker brought together a group of five established healthcare advocates under the umbrella GLAM, short for Great Life After Menopause. The advocates will keep their distinct voices, which are anything but muted.

Astellas serves up dose of "reality" in DTC effort

Astellas serves up dose of "reality" in DTC effort

By

The drug maker's broadcast-heavy "OAB reality" campaign stresses the emotional toll on women.

Business briefs: J&J, Manhattan Research, plus July job cuts

J&J sells off its feminine side; Manhattan Research's study on the sales rep "tablet dance"; Cepheid rolls out a consumer TB campaign; and healthcare sector job losses top out in July.

Merck braces for revenue shortfall amid patent losses

By

Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.

HPV vaccination rates losing ground, CDC reports

By

The CDC says HPV vaccination rates are not improving. The latest data comes just as a recent report shows the vaccine cannot only help fend off cervical cancer, but throat cancers as well.

Hot-flash med could open up women's health category

Hot-flash med could open up women's health category

By

The first prescription non-hormonal treatment offers relief for women who do not want to tangle with hormone-replacement therapy.

Business briefs: Medtronic, AMA, Komen, GSK, Lilly, AZN

Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site

Business briefs: Teva, Celgene, Komen, Apple, OPDP

Plan B age limits retained and rejected, Celgene drugs gets expanded indication, Komen cuts back on walks, Apple is policing medical apps, OPDP director's Q&A

Duchesnay returns morning sickness drug to US market

By

The first drug for morning sickness in thirty years enters the market this month.

Business briefs: HRT, HPV, Novo Nordisk

Researchers find weaknesses in HRT-breast cancer studies, Novo announces GLP-1 weight loss results

FDA cracks down on sleep aids

FDA cracks down on sleep aids

By

The regulator tells manufacturers to halve the recommended doses of zolpidem sleep-aids. Purdue Pharma's Intermezzo already hits the mark, but the drugmaker doesn't anticipate a sales jump or new messaging strategy.

Email Newsletters